Biogen

News

Leqembi approved in Japan, its first ex-US market

Eisai and Biogen now have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.

News

Grogan named Biogen research chief as reset continues

Chris Viehbacher's efforts to reinvigorate Biogen are continuing to take shape with the appointment of industry veteran Jane Grogan to the position of head of research.

News

Sage sheds staff after narrow Zurzuvae approval

Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

News

Sage considering cuts after FDA setback

Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the

News

Zuranolone cleared for post-partum depression, but not MDD

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ

Leqembi approved in Japan, its first ex-US market

Grogan named Biogen research chief as reset continues

Sage sheds staff after narrow Zurzuvae approval

First Tysabri biosimilar cleared by FDA for MS

Sage considering cuts after FDA setback

Zuranolone cleared for post-partum depression, but not MDD

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Biogen

Editor's Picks